Compare
Sarepta Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc. vs United Therapeutics Corp vs Phibro Animal Health Corp
| Latest fiscal year | Sarepta Therapeutics, Inc. SRPT | Amneal Pharmaceuticals, Inc. AMRX | United Therapeutics Corp UTHR | Phibro Animal Health Corp PAHC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $2.20B | $3.02B | $3.18B | $1.52B |
| Revenue growth (YoY) | +15.6% | +8.0% | +10.6% | +17.1% |
| Gross margin | n/a | 36.9% | 87.9% (computed) | 33.8% |
| Operating margin | -31.8% | 13.1% | 46.9% | 12.8% |
| Net margin | -32.5% | 2.4% | 41.9% | 6.6% |
| Net income | -$713.41M | $72.06M | $1.33B | $99.72M |
| EPS (Diluted) | -$7.13 | $0.22 | $27.86 | $2.43 |
| Operating cash flow | -$205.48M | $339.99M | $1.56B | $68.95M |
| Free cash flow | -$307.45M | $269.93M | $1.04B | $9.87M |
| Cash & equivalents | $801.28M | $282.03M | $1.56B | $61.42M |
| Total assets | $3.35B | $3.68B | $7.88B | $1.50B |
| Total liabilities | $2.21B | n/a | $783.80M | $1.12B |
| Shareholders' equity | $1.14B | -$70.79M | $7.10B | $385.48M |
| Return on year-end equity | -62.5% | n/a | 18.8% | 25.9% |
| Shares outstanding | 104.96M | n/a | 43.64M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Sarepta Therapeutics, Inc. | Amneal Pharmaceuticals, Inc. | United Therapeutics Corp | Phibro Animal Health Corp |
|---|---|---|---|---|
| Latest | $2.20B Ended 2025-12-31 | $3.02B Ended 2025-12-31 | $3.18B Ended 2025-12-31 | $1.52B Ended 2026-06-30 |
| 1 year earlier | $1.90B Ended 2024-12-31 | $2.79B Ended 2024-12-31 | $2.88B Ended 2024-12-31 | $1.30B Ended 2025-06-30 |
| 2 years earlier | $1.24B Ended 2023-12-31 | $2.39B Ended 2023-12-31 | $2.33B Ended 2023-12-31 | $1.02B Ended 2024-06-30 |
| 3 years earlier | $933.01M Ended 2022-12-31 | $2.21B Ended 2022-12-31 | $1.94B Ended 2022-12-31 | $977.89M Ended 2023-06-30 |
| 4 years earlier | $701.89M Ended 2021-12-31 | $2.09B Ended 2021-12-31 | $1.69B Ended 2021-12-31 | $942.26M Ended 2022-06-30 |